Litcius/Paper detail

Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib

Ghazi Elamin, Aimen Aljoundi, Mohammed Issa Alahmdi, Nader E. Abo‐Dya, Mahmoud E. S. Soliman

2022Journal of Molecular Modeling12 citationsDOI

Topics & Concepts

Bruton's tyrosine kinaseChemistryMutantIbrutinibTyrosineBiochemistryComputational biologyBiophysicsTyrosine kinaseGeneticsBiologySignal transductionGeneChronic lymphocytic leukemiaLeukemiaChronic Lymphocytic Leukemia ResearchPI3K/AKT/mTOR signaling in cancerLymphoma Diagnosis and Treatment
Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib | Litcius